小金丹及其联合治疗方案治疗甲状腺结节有效性及安全性的Meta分析  

Efficacy and Safety of Xiaojindan and Its Combination Therapy in the Treatment of Thyroid Nodules: A Meta-Analysis

作　　者：余丝思 郭力 李昱 范馨予 

机构地区：[1]黑龙江省中医药科学院,黑龙江 哈尔滨 [2]黑龙江省中医医院内分泌三科,黑龙江 哈尔滨

出　　处：《中医学》2024年第12期3577-3586,共10页Traditional Chinese Medicine

摘　　要：目的:系统评价小金丹及其联合治疗方案治疗甲状腺结节的有效性及安全性。方法:计算机检索CBM、WanFang Data、CNKI、VIP、PubMed、EMbase、The Cochrane Library和Web of Science数据库,搜集有关小金丹及其联合治疗方案治疗甲状腺结节的随机对照试验(RCTS),检索时限均为建库至2024年10月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果:共纳入8个RCTS,包括692例患者。Meta分析结果显示:与对照组相比,小金丹组的总有效率明显更高[RR = 1.30, 95% CI (1.18, 1.44), p p = 0.001],减少不良反应的发生[RR = −0.34, 95% CI (0.22, 0.53), p Objective: Evaluate the efficacy and safety of Xiaojindan and its combination therapy in the treatment of thyroid nodules. Methods: Search related literature in CBM, WanFang Data, CNKI, VIP, PubMed, Embase, The Cochrane Library, and Web of Science databases. Randomized controlled trials (RCTS) of Xiaojindan and its combination regimen in the treatment of thyroid nodules were collected from the database until October 2024. Meta-analysis was performed using RevMan 5.4 software after two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the study. Results: A total of 8 RCTS were included, including 692 patients. The results of the meta-analysis showed that compared with the control group, the total effective rate of the Xiaojindan group was significantly higher [RR = 1.30, 95% CI (1.18, 1.44), p p = 0.001]. The incidence of adverse reactions was reduced [RR = −0.34, 95% CI (0.22, 0.53), p < 0.00001]. Conclusion: The current evidence shows that Xiaojindan and its combined treatment regimen can effectively treat thyroid nodules and reduce the occurrence of adverse reactions. The above conclusions need to be verified by more high-quality studies.

关 键 词：小金丹 甲状腺结节 META分析 随机对照试验 

分 类 号：R73[医药卫生—肿瘤]